Related Experiment Video
Updated: Aug 5, 2026
07:03
Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
Published on: October 2, 2020
An Integrated Cellular Computational Pipeline Decodes Luteolin to Design Possible Allosteric CDK1/CYCLIN B1
Rajesh Basnet1,2, Buddha Bahadur Basnet3, Muhammad Majid1
1Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Pharmaceuticals (Basel, Switzerland)
|July 28, 2026
Summary
The natural compound luteolin (LT) inhibits the CDK1/Cyclin B1 complex, a key driver of breast cancer (BC) progression. This dual mechanism suppresses tumor growth and BC stemness, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- CDK1/Cyclin B1 complex dysregulation is a hallmark of breast cancer (BC) progression.
- The natural flavonoid luteolin (LT) exhibits anti-cancer properties, but its precise mechanism against CDK1/CCNB1 is not well understood.
Purpose of the Study:
- To elucidate the mechanism by which luteolin targets the CDK1/Cyclin B1 complex in breast cancer.
- To evaluate the anti-proliferative and stemness-modulating effects of luteolin and its analogues.
Main Methods:
- Gene expression profiling of CDK1, CCNB1, and CCNB2 in normal and BC cell lines.
- Utilized an engineered HEK293T cell model to assess luteolin's impact on proliferation, ROS, and gene transcription.
- Employed computational methods including molecular docking, dynamics simulations, and network pharmacology to analyze luteolin-CDK1/CCNB1 interactions and pathways.
Main Results:
- Luteolin suppressed CCNB1 transcription, correlating with reduced proliferation and modulated ROS levels.
- Computational analyses confirmed stable binding of luteolin to the CDK1/Cyclin B1 complex.
- Network pharmacology identified cell cycle regulation, particularly in BC stem cells, as a key targeted pathway.
Conclusions:
- Luteolin and its designed analogues effectively inhibit the CDK1/Cyclin B1 complex.
- This inhibition demonstrates a dual mechanism targeting both tumor growth and breast cancer stemness.
- Luteolin represents a promising therapeutic agent for breast cancer treatment.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
01:28The Cell Cycle Control System
The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...